Immune System Diseases

All Conditions

Neoplasms

Digestive System Diseases

Gland and Hormone Related Diseases

Rare Diseases

Hypersensitivity

Pancreatic Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Gastrointestinal Diseases

Pancreatic Diseases

Endocrine System Diseases

Pancreatic Cancer

Tumoroid formation and drug sensitivity analysis

Inditreat

Second line treatment based on drug sensitivity analysis

Experimental drug

Lars Henrik Jensen, MD, PhD

It will be investigated whether it is possible to predict the effect or lack of effect of first-line treatment by analysing cancer cells from the individual patient receiving standard first line treatment. Also, the feasibility of selecting second-line therapy based on pre-treatment biopsies will be investigated.

Cells from pancreatic cancer will be grown in the laboratory to form small, circulating tumors and adjacent tissue, so called tumoroids. The tumoroids will then be exposed to different pre-specified anticancer drugs to hopefully reveal sensitivity or lack of sensitivity in the specific patient.

Predictive Value of Analysing Tissue From Patients With Metastatic Pancreatic Cancer for Drug Sensitivity

Predictive Value of In-vitro Anti-cancer Therapy Sensitivity Testing on Tumoroids From Patients With Metastatic Pancreatic Cancer

Predictive value is defined as the ability to correctly predict response or resistance to first-line chemotherapy

Vejle Hospital

Symptoms and General Pathology

Neoplasm Metastasis

Colorectal Neoplasms

Liver Neoplasms

Intestinal Neoplasms

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Neoplastic Processes

Liver Diseases

Antineoplastic Agents

All Drugs and Chemicals

Hematinics

Bevacizumab

Tislelizumab

Cetuximab

Immunomodulating Agents

Liver Extracts

Tislelizumab Combined With XELOX and Bevacizumab or Tislelizumab Combined With FOLFOX and Cetuximab

Tilelizumab combined with XELOX and bevacizumab or tislelizumab combined with FOLFOX and cetuximab

Ying Yuan, MD

Xuefeng Fang, phD

Ying Yuan

Evaluation of tislellimab combined with XELOX and bevacizumab or tislelizumab combined with FOLFOX and cetuximab regimen in patients with liver metastases from colorectal cancer Rate and R0 resection rate and safety.

Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status

Drug safety assessed by CTCAE v4.0; Incidence of Treatment-Emergent Adverse Events \[Safety and Tolerability\]

objective response rate based on RECIST1.1

Disease control rate % based on RECIST1.1

Second Affiliated Hospital, School of Medicine, Zhejiang University

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Predictive Value of Analysing Tissue From Patients With Metastatic Pancreatic Cancer for Drug Sensitivity	NCT03821870	Metastatic Panc...	Inditreat Experimental dr...	18 Years -	Vejle Hospital
Predictive Value of Analysing Tissue From Patients With Metastatic Pancreatic Cancer for Drug Sensitivity	NCT03821870	Metastatic Panc...	Inditreat Experimental dr...	18 Years -	Vejle Hospital
Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status	NCT05409417	Colorectal Canc... Liver Metastase...	Experimental dr...	18 Years - 75 Years	Second Affiliated Hospital, School of Medicine, Zhejiang University

Spots Global Cancer Trial Database for experimental drug